Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

• Yuankai Shi ,

  * E-mail: syuankai@cicams.ac.cn

  Affiliation Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No.17 Panjiayuan Nanli, Chaoyang District, Beijing (100021), China

  ⨯
• Junling Li,

  Affiliation Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No.17 Panjiayuan Nanli, Chaoyang District, Beijing (100021), China

  ⨯
• Shucai Zhang,

  Affiliation Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing (1011429), China

  ⨯
• Mengzhao Wang,

  Affiliation Department of Respiration Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing (100005), China

  ⨯
• Shujun Yang,

  Affiliation Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou (450008), Henan Province, China

  ⨯
• Ning Li,

  Affiliation Department of Medical Oncology, Guangzhou Chest Hospital, Guangzhou (510095), Guangdong Province, China

  ⨯
• Gang Wu,

  Affiliation Cancer Center, Union Hospital, Tongji Medical College HuaZhong University of Science and Technology, Wuhan (430030), Hubei Province, China

  ⨯
• Wei Liu,

  Affiliation Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang (050035), Hebei Province, China

  ⨯
• Guoqing Liao,

  Affiliation Department of Medical Oncology, The 309th Hospital of Chinese People’s Liberation Army, Beijing (100091), China

  ⨯
• Kaican Cai,

  Affiliation Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou (510515), Guangdong Province, China

  ⨯
• Liang’an Chen,

  Affiliation Department of Respiration Medicine, Chinese People’s Liberation Army General Hospital, Beijing (100853), China

  ⨯
• Meizhen Zheng,

  Affiliation Department of Medical Oncology, Liaoning Cancer Hospital, Shenyang (110042), Liaoning Province, China

  ⨯
• Ping Yu,

  Affiliation Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu (610041), Sichuan Province, China

  ⨯
• Xiuwen Wang,

  Affiliation Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan (250012), Shandong Province, China

  ⨯
• Yunpeng Liu,

  Affiliation Department of Medical Oncology, The First Hospital of China Medical University, Shenyang (110001), Liaoning Province, China

  ⨯
• Qisen Guo,

  Affiliation Department of Medical Oncology, Shandong Cancer Hospital, Jinan (250117), Shandong Province, China

  ⨯
• Ligong Nie,

  Affiliation Department of Respiration Medicine, Peking University First Hospital, Beijing (100034), China

  ⨯
• Jiwei Liu,

  Affiliation Department of Medical Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian (116011), Liaoning Province, China

  ⨯
•  [ ... ],
• Xiaohong Han

  Affiliation Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No.17 Panjiayuan Nanli, Chaoyang District, Beijing (100021), China

  ⨯
• [ view all ]
• [ view less ]